Botanix Pharmaceuticals Limited (ASX: BOT) has disclosed a spectacular first quarter for FY26 that was aided by a swift Sofdra sales increase and better cash flow efficiency. The specialist in dermatology announced the growth of the Botanix Pharmaceuticals Sofdra revenue by 65%, based on the Botanix Pharmaceuticals Q1 FY26 results and Appendix 4C from $4.3 million in Q4 FY25 to $7.1 million in Q1 FY26.
Moreover, total prescriptions increased by 50%, rising from 13,647 in Q4 FY25 to 20,418 in Q1 FY26. The company indicated that the vigorous performance was owing to the increase in physician adoption, strong refill rates, and wide patient access in the US.
Botanix mentioned that the early commercial momentum for its Sofdra® (sofpironium) topical gel 12.45 % is a sign of the growing acceptance by dermatologists and the patients treating primary axillary hyperhidrosis. These figures highlight that Sofdra’s prescription growth in 2025 remains a major driver of Botanix’s success story.
Botanix Pharmaceuticals reports 65% Sofdra revenue growth in Q1 FY26.
What Is Driving Sofdra Prescription Growth In 2025?
The Sofdra prescription growth 2025 trend was a clear indication of the company’s careful commercial rollout and focused expansion of the U.S. sales force. Botanix expanded its sales team to 50 sales professionals as of 20 October 2025, which resulted in better coverage across the main dermatology markets.
Furthermore, the enhanced Gross-to-Net (GTN) revenue performance was also a factor that contributed to the success of the Botanix Pharmaceuticals Q1 FY26 results. In Q1 FY26, the GTN improved to 23%, which is an increase from the previous quarter’s 21%, and the improvement was due to better insurance coverage and operational efficiencies. The company is now aiming for an average GTN of 30%-40%, which is in line with the leading U.S. dermatology peers.
Botanix gross Sofdra sales amounted to $30.2 million versus $20.4 million for Q4 FY25, which is an indication of the rapid revenue trajectory of its leading therapy and reinforces confidence in Botanix Pharmaceuticals’ Sofdra revenue.
Can Botanix Sustain Its Sofdra Momentum?
Botanix Pharmaceuticals has made it a priority to keep the momentum going. The firm indicated that good refill numbers, growing doctors’ confidence, and better reimbursement access are the factors that will drive Sofdra prescription growth in 2025 even further into Q2 FY26.
The company has an excellent balance sheet, with cash accounting for $49.2 million as of September 30, 2025. Botanix is ready to supply current sales and support further expansion in the next quarter without additional API purchases, as they already have sufficient inventory in place.
The management is still confident that the previous investment in the manufacturing and commercial infrastructure has finally started to yield measurable returns. The rising Sofdra prescriptions indicate the product’s long-term survival in the competitive dermatology market, adding further credibility to Botanix Pharmaceuticals’ Sofdra revenue and its future earnings outlook.
Botanix aims to sustain Sofdra’s growth through refills and confidence.
What Do The Botanix Pharmaceuticals Q1 FY26 Results Indicate For Investors?
The Botanix Pharmaceuticals Q1 FY26 results have put several encouraging signals for investors. The considerable rise in net revenue and prescriptions is proof of strong market acceptance. The operating cash outflow also significantly improved it going down by 54 %, from $28.4 million in Q4 FY25 to $13.1 million in Q1 FY26.
Additionally, product manufacturing costs experienced an 81 % reduction, from $11.2 million to $2.2 million, which has been a sign of stabilisation at steady-state production levels. This huge cost benefit was taken as a result of lower raw material purchases and the efficient turning of inventory into finished products.
Such operational discipline has allowed Botanix to create a scenario where the coming quarters will be characterised by lower cash burn, accompanied by a commercial growth trajectory strengthening Botanix Pharmaceuticals’ Sofdra revenue.
Strategic Outlook: Sofdra Positioned For Continued Expansion
Botanix has forecasted a further strengthening of its U.S. market presence in FY26. The growth outlook for Sofdra is still very strong due to the increased sales team and the better gross margins. The company plans to strengthen the ties with the dermatologists, raise patient awareness, and use data-driven marketing initiatives that underpin the company’s success.
In the longer term, Botanix intends to become profitable by increasing its revenue, along with taking measures to improve the GTN. As the market is penetrated deeper, it is expected that the revenues will go up owing to the higher insurance coverage. The analysts regard the early success of the brand as a sure and promising basis for the international markets and for maintaining strong Botanix Pharmaceuticals Sofdra revenue momentum.
Botanix Pharmaceuticals Limited Share Trend
Why This Quarter Marks A Turning Point
This quarter is a landmark for Botanix as it marks the company’s transition from being a development-stage biotech to a revenue-generating pharmaceutical company. The remarkable increase in Sofdra’s sales confirms the company’s investment in R&D and strategic planning over the years.
The better operating cash flow and effective stock management illustrate once more that Botanix is a company that knows how to mix growth with financial discipline. The company has cash reserves amounting to $49.2 million, which enables it to fund its next phase of commercial acceleration without the need for immediate external financing.
The market will be closely watching the development of Botanix as the company consolidates the market share of Sofdra. Investors and analysts alike are expected to monitor Botanix Pharmaceuticals’ Sofdra revenue and the continuation of Sofdra prescription growth in 2025 as FY26 unfolds.
Also read: Island Pharmaceuticals Advances Galidesivir with FDA Type C Meeting Secured
Frequently Asked Questions
Q1: What was the Sofdra net revenue in Q1 FY26?
A: Sofdra’s net revenue amounted to $7.1 million, representing a 65 % increase from $4.3 million in Q4 FY25.
Q2: How many Sofdra prescriptions were shipped during the quarter?
A: Botanix shipped 20,418 Sofdra prescriptions, representing a 50 % increase compared to the previous quarter, where 13,647 prescriptions were shipped.
Q3: How much cash does Botanix hold as of 30 September 2025?
A: At the end of the quarter, the company reported a cash position of $49.2 million.
Q4: What improvements were made in operational spending?
A: The cash outflow from operations decreased from $28.4 million to $13.1 million, and manufacturing costs dropped by 81 % to $2.2 million.
